Movement Alert｜QingSong Health Rises 9.68% in Regular Trading, AI Evidence-Based Medical Partnerships and Buyback Plan Continue to Boost Sentiment

Market Focus06-25

On June 25, QingSong Health rose 9.68% in regular trading, trading at HK$14.17/share, with turnover of HK$58.44 million. The rally was driven by a series of recent positive developments reinforcing market confidence in the companys AI-powered healthcare commercialization trajectory.

On the news front, the company recently signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) to build an intelligent rare disease screening and full-cycle health management system powered by its proprietary evidence-based medicine AI agent ZhengYuanFang. Simultaneously, QingSong Health entered a three-year strategic MOU with Basel Medical Group to jointly expand into Southeast Asian markets. Additionally, controlling shareholder Yang Yin voluntarily extended her share lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million in shares from the open market. The combined lock-up extension and buyback program effectively alleviates prior market concerns over post-lockup selling pressure, sustaining bullish momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122061344?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 13:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122061344","market":"us","top_or_hot":-1,"title":"Movement Alert｜QingSong Health Rises 9.68% in Regular Trading, AI Evidence-Based Medical Partnerships and Buyback Plan Continue to Boost Sentiment","media":"Market Focus","content":"<p><p>On June 25, QingSong Health rose 9.68% in regular trading, trading at HK$14.17/share, with turnover of HK$58.44 million. The rally was driven by a series of recent positive developments reinforcing market confidence in the companys AI-powered healthcare commercialization trajectory.</p><p>On the news front, the company recently signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) to build an intelligent rare disease screening and full-cycle health management system powered by its proprietary evidence-based medicine AI agent ZhengYuanFang. Simultaneously, QingSong Health entered a three-year strategic MOU with Basel Medical Group to jointly expand into Southeast Asian markets. Additionally, controlling shareholder Yang Yin voluntarily extended her share lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million in shares from the open market. The combined lock-up extension and buyback program effectively alleviates prior market concerns over post-lockup selling pressure, sustaining bullish momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜QingSong Health Rises 9.68% in Regular Trading, AI Evidence-Based Medical Partnerships and Buyback Plan Continue to Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜QingSong Health Rises 9.68% in Regular Trading, AI Evidence-Based Medical Partnerships and Buyback Plan Continue to Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 13:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, QingSong Health rose 9.68% in regular trading, trading at HK$14.17/share, with turnover of HK$58.44 million. The rally was driven by a series of recent positive developments reinforcing market confidence in the companys AI-powered healthcare commercialization trajectory.</p><p>On the news front, the company recently signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) to build an intelligent rare disease screening and full-cycle health management system powered by its proprietary evidence-based medicine AI agent ZhengYuanFang. Simultaneously, QingSong Health entered a three-year strategic MOU with Basel Medical Group to jointly expand into Southeast Asian markets. Additionally, controlling shareholder Yang Yin voluntarily extended her share lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million in shares from the open market. The combined lock-up extension and buyback program effectively alleviates prior market concerns over post-lockup selling pressure, sustaining bullish momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02661","symbol_name":"轻松健康","start_time":0,"source_url":"","article_id":"1122061344","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122061344","pubTimestamp":1782366613,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, QingSong Health rose 9.68% in regular trading, trading at HK$14.17/share, with turnover of HK$58.44 million. The rally was driven by a series of recent positive developments reinforcing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02661":"轻松健康"},"translate_title":"动向提示|青松健康常规交易涨9.68%AI循证医疗合作伙伴关系及回购计划持续提振人气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02661":1},"content_text":"On June 25, QingSong Health rose 9.68% in regular trading, trading at HK$14.17/share, with turnover of HK$58.44 million. The rally was driven by a series of recent positive developments reinforcing market confidence in the companys AI-powered healthcare commercialization trajectory.On the news front, the company recently signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) to build an intelligent rare disease screening and full-cycle health management system powered by its proprietary evidence-based medicine AI agent ZhengYuanFang. Simultaneously, QingSong Health entered a three-year strategic MOU with Basel Medical Group to jointly expand into Southeast Asian markets. Additionally, controlling shareholder Yang Yin voluntarily extended her share lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million in shares from the open market. The combined lock-up extension and buyback program effectively alleviates prior market concerns over post-lockup selling pressure, sustaining bullish momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122061344","isCrawlerRequest":true}